APTX:NSD-Aptinyx Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.97

Change

+0.16 (+4.20)%

Market Cap

USD 0.24B

Volume

1.21M

Average Target Price

USD 11.25 (+183.38%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.04 (+0.46%)

USD58.95B 22.22 17.39
REGN Regeneron Pharmaceuticals, Inc

+1.98 (+0.39%)

USD54.85B 18.84 14.53
MRNA Moderna, Inc

+25.71 (+20.24%)

USD50.27B N/A N/A
SGEN Seagen Inc

+1.19 (+0.70%)

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

-1.72 (-1.39%)

USD27.10B 28.74 26.92
BNTX BioNTech SE

+14.25 (+12.96%)

USD26.48B -99,999.99 N/A
RPRX Royalty Pharma plc

+1.00 (+2.40%)

USD26.01B 22.60 9.74
GMAB Genmab A/S

+1.48 (+3.99%)

USD24.32B 26.59 2.61
BGNE BeiGene, Ltd

-30.20 (-10.56%)

USD24.20B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing APTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.08% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.08% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 3.12% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.12% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.06% N/A N/A 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.06% N/A N/A 7% F
Risk Return Profile  
Volatility (Standard Deviation) 38.70% N/A N/A 34% F
Risk Adjusted Return -62.19% N/A N/A 11% F
Market Capitalization 0.24B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.20 N/A N/A N/A N/A
Price / Cash Flow Ratio -4.63 N/A N/A N/A N/A
EV/EBITDA 0.14 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -46.04% N/A N/A N/A N/A
Return on Invested Capital -47.57% N/A N/A N/A N/A
Return on Assets -28.49% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.53 N/A N/A N/A N/A
Short Percent 4.04% N/A N/A N/A N/A
Beta 1.23 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.